At the ongoing International Society for Stem Cell Research meeting, Chinese researchers reported they demonstrated that SPT6 homolog, histone chaperone and transcription elongation factor (SPT6) ...

Med-tech M&A activity dipped in May, reaching $1.52 billion, down from $2.07 billion in April and a far cry from the highs ...

In what represents the company’s first filing, the co-founders of Pharmalytix Inc., Sierra Houang and Lee Grady, describe ...

Medtronic plc received U.S. FDA approval for its Omniasecure defibrillation lead for placement in the right ventricle to ...

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in ...

Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of ...

The lack of therapeutic precision in treatment of myeloid malignancies is in sharp contrast with the fact that myeloid cancers represent the perhaps best characterized cancers of all at the cellular, ...

The BioWorld Neurological Diseases Index continued its downward slide into 2025, with 15 of the 20 component stocks posting losses. After dipping into negative territory in late February, the index ...

Urogen Pharma Ltd. plans to launch its new product July 1 after the firm overcame a decidedly mixed FDA advisory panel meeting to nail down approval June 12 of Zusduri (mitomycin, formerly known as ...

Four biotech companies from South Korea announced new or planned financings mid-June, including GC Genome Corp. Rznomics Inc., G2Gbio Inc. and Mezzion Pharma Co. Ltd. Six major mid-June deals included ...

Celldex Inc.’s KIT inhibitor, barzolvolimab, which hit its phase II endpoints in late 2023, kicking off phase III development in chronic spontaneous urticaria, offered up some impressive long-term ...